Archer Materials Limited AXE.AX

IR documents · Reporting currency AUD · Figures as of FY2026 · updated 2026-09-04 · ISIN AU000000AXE7

strategy: Strategic pivot strategy: New market Net income turned positive ◦

The new quarter, in context. · We follow every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.

AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more

AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.

Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.

Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.

EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology

AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.

Business Model#

What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own.

Archer Materials Limited is an early-stage Australian technology company developing two proprietary platforms: the 12CQ quantum computing chip, built on carbon-based graphene qubit spin technology licenced from the University of Sydney, and a point-of-care Biochip medical diagnostics platform targeting rapid clinical testing. Neither platform has reached commercialisation and the company records no operating revenue. Archer funds its operations through equity capital raisings and Australian government R&D tax incentive programmes. In FY2026 the company advanced the 12CQ program by demonstrating two readout methods (EDMR and single-electron transistors) and achieving carbon qubit synthesis on a one-inch silicon wafer with electron spin lifetimes exceeding 0.4 microseconds at room temperature. The Biochip platform reached integrated alpha prototype stage, with the IMEC collaboration extended to silicon-based sensors and beta prototype development underway for external laboratory and pre-clinical evaluation. A post-period Quantum Compute Agreement with IonQ provides cloud-based quantum computing access for a three-year term, and a CSIRO joint project commenced in November 2025 targets quantum machine-learning software for financial fraud detection. The intended path to monetisation runs through advancing both platforms to foundry-ready and pre-clinical evaluation stages before engaging commercialisation partners for licensing or co-development arrangements.

Current Status#

Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number.

For the financial year ended 30 June 2026, Archer Materials recorded a net loss of $6,361,253, an 8.8% improvement from $6,972,006 in FY2025, with a net cash position of $8,419,013 and no corporate debt at year end. ⁶ Cash and cash equivalents stood at $2.7 million at 31 December 2025 ¹⁰⁶, declining to $1,845,647 at 30 June 2026. ⁶ During FY2026, the company completed the integrated alpha prototype for its Biochip platform, demonstrated two readout methods in carbon-based quantum devices under the 12CQ program, and achieved carbon qubit synthesis on a one-inch silicon wafer with electron spin lifetimes exceeding 0.4 microseconds at room temperature. ⁶ Subsequent to year end, a three-year Quantum Compute Agreement with IonQ was signed and equity raisings totalling approximately $7,813,321 before costs were completed through a placement and Share Purchase Plan. ⁶

Management commentary on the FY2026 results (IR-Annual, 2026-08-26):

„We do not intend to wait for a future quantum computer to arrive in Australia before building the business around it.“ – Greg English, Executive Chair ⁶

Net profit · FY2026-6A$m+8.6 % vs. FY2025

EPS · FY2026-2.50A$+8.8 % vs. FY2025

Profitability

Net loss for FY2026 was $6,361,253, compared with $6,972,006 in FY2025, with the $610,753 (8.8%) year-on-year improvement driven by lower share-based payments expense. ⁶ The company generated no operating revenue; the R&D tax incentive receivable was $2,351,354 for FY2026, up from $2,055,447 in the prior year. ⁶ Operating cash outflow for the year was $5,253,164. ⁶

Leverage

Archer held a net cash position of $8,419,013 and no corporate debt at 30 June 2026, with cash and cash equivalents of $1,845,647 at the same date. ⁶ Net cash declined by $5,325,687 from $13,744,700 at the prior year end, reflecting ongoing R&D expenditure with no revenue to offset outflows. ⁶ Subsequent to year end, a placement tranche raising approximately $6,860,000 and a Share Purchase Plan raising $953,321, both before costs, were completed in July and August 2026 respectively, providing additional liquidity. ⁶

Management view

Archer entered into a three-year Quantum Compute Agreement with IonQ on 1 July 2026, providing access to IonQ Quantum Cloud and specialist engineering support for total payments of $1,500,000 USD. ⁶ The Biochip collaboration with IMEC was expanded during FY2026 to incorporate silicon-based sensors offering faster readout and lower manufacturing risk, and beta prototype development for external laboratory testing and pre-clinical evaluation commenced. ⁶ A joint project with CSIRO commenced in November 2025 to develop quantum machine-learning software targeting financial fraud detection, extending the 12CQ program's application roadmap. ⁶

Change

Cash and cash equivalents fell from $2,661,950 at 30 June 2025 to $1,845,647 at 30 June 2026, reflecting ongoing operational outflows with no revenue offset during the year. ⁶ The Quantum TMR sensor project completed its technical evaluation during FY2026 and transitioned to an assessment phase focused on identifying potential lead applications, marking a change in the scope of that workstream. ⁶ Performance rights totalling 1,474,962 shares and 1,085,391 shares were issued to employees and key management personnel in September and November 2025 respectively, both with an expiry date of 30 June 2030. ⁶

Risks (current)

Commercialisation of the 12CQ technology is contingent on the licence agreement with the University of Sydney remaining in place, while access to IonQ quantum computing resources depends on the Quantum Compute Agreement remaining in force; termination of either would block the respective commercialisation pathway. ⁶ The Biochip platform's IP position relies on patent protection against third-party claims, and medical device development requires compliance with TGA, FDA, and European regulatory standards, where delays or non-compliance could stall product development. ⁶ The company's cash position at 30 June 2026 highlights continued dependence on external equity funding to sustain operations, there is no guarantee of securing suitable customers and partners for the IonQ quantum computer sovereign capability initiative, and patents and licences under prosecution require annual fees to maintain access. ⁶

New this reporting period

Archer completed the integrated alpha prototype for its Biochip platform by 30 June 2026 and commenced beta prototype development for external laboratory testing and pre-clinical evaluation. ⁶ The company signed a three-year Quantum Compute Agreement with IonQ on 1 July 2026 and expanded the IMEC collaboration during FY2026 to add silicon-based sensors to the Biochip platform. ⁶ A joint project with CSIRO commenced in November 2025 to develop quantum machine-learning software for financial fraud detection as part of the 12CQ commercialisation roadmap. ⁶

Price & Chart#

Interactive price chart (TradingView) and the trend of key figures from the core tables. The price chart loads only after a click; at that point a connection to TradingView is established.

Daily candles with news and earnings markers. Loads only on click.

Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.

Share-Price Drivers#

Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own.

Deep-tech commercialisation across three pre-revenue technology platforms (12CQ quantum chip, Biochip, TMR sensor)
Company remains pre-revenue with no segment sales reported; value hinges on advancing prototypes toward foundry-ready and clinical milestones while funding operations from a small cash base of A$2.7m at 2025-Q4 (¹⁰⁶) supplemented by a $7m placement (⁵)

IonQ Strategic Quantum Compute Agreement
Strategic Quantum Compute Agreement with IonQ Inc. signed 2026-07-09, following the earlier IonQ Quantum Compute Agreement (⁵, ⁶)

Biochip development progress (blood-potassium sensing)
Integrated alpha prototype completed 2026-06-30 (Launched), with beta prototype development commencing and external-laboratory/pre-clinical evaluation planned (⁶, ⁵)

12CQ quantum chip toward foundry-readiness
12CQ quantum chip foundry-ready demonstration and qubit demonstrator device planned for 2026 (⁵, ⁴, ¹)

TMR sensor commercialisation pathway
TMR sensor commercialisation pathway establishment noted from FY2025; IMEC collaboration expanded to silicon-based sensors (Launched) (¹, ⁶)

Capital raising and funding runway
$7m share placement (Launched) plus a Share Purchase Plan for eligible Australian and New Zealand shareholders in 2026-Q4; cash A$2.7m (2025-Q4) vs A$2.8m (2024-Q4) and A$0.8m (2023-Q4) (⁵, ¹⁰⁶, ¹⁰¹)

Research collaborations
CSIRO joint project for quantum machine-learning software (Launched, 2025-11) and full Quantum Machine Learning prototype for fraud detection planned (⁶, ⁴)

Sector trend: As a pre-revenue deep-tech developer, Archer reports no segment revenue or margins; activity is trending toward more advanced prototype and partnership milestones (IonQ agreement, Biochip alpha prototype, IMEC/CSIRO collaborations), while operations continue to draw on a modest cash base funded by equity raisings (⁵, ⁶, ¹⁰⁶).

Event Timeline#

This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Events are grouped by quarter (most recent first); the grey tag before each event names the event type, the date is the publication date of the source. Management quotes open the quarter block as direct quotes. Per quarter we show the three most defining events; more can be expanded per quarter, older years are collapsed. Every event carries its source as a superscript, clickable number.

Overview: one dot per event · click jumps to the period

2026 · 8 events

FY2026 · Jul 2025 – Jun 2026

„We do not intend to wait for a future quantum computer to arrive in Australia before building the business around it.“ – Greg English, Executive Chair ⁶

Net income turned positive ◦ 2026-08-26
Net loss narrowed 8.8% to A$6.36M (FY25: A$6.97M), driven by lower share-based payments expense (non-cash item); underlying research expenditure broadly unchanged (⁶)

Strategic pivot 2026-08-26
Expanded Biochip platform via IMEC collaboration to include silicon-based sensors offering faster readout and lower manufacturing risk alongside existing graphene-based approach (⁶)

New market 2026-08-26
12CQ milestone: carbon qubit material synthesised on one-inch silicon wafer with electron spin lifetimes exceeding 0.4 microseconds demonstrated at room temperature (⁶)

2026-Q4 · Apr – Jun 2026

„We've had a tremendous quarter for the business, alongside significant commercial momentum, we also delivered across all three pillars of our technology portfolio. To have all programs making consistent progress in the most exacting and challenging markets in the world is a testament to the enormous talent of the Archer team.“ – Dr Simon Ruffell, Chief Executive Officer ⁵

Strategic pivot 2026-06-30
Announced Quantum Compute Agreement with IonQ Inc. to access global commercial quantum hardware for algorithm development (⁵)

New market 2026-06-30
Quantum neural network detected 18 of 19 fraudulent transactions on commercial quantum hardware, demonstrating algorithm performance beyond simulation (⁵)

New market 2026-06-30
Completed full-wafer manufacturing runs of refined 12CQ graphene qubit spin designs with improved performance and fabrication scalability (⁵)

2026-Q3 · Jan – Mar 2026

„We also progressed our partnership with Emergence Quantum, laying the groundwork for identifying graphene-based prototype applications.“ – Greg English, Executive Chairman ⁴

New market 2026-06-30
Biochip alpha-prototype demonstrated clinically relevant potassium sensing accuracy within ±0.3 mM; beta-prototype planned for later in 2026 (⁴)

New market 2026-06-30
Completed first phase of quantum machine-learning models for financial fraud detection; full prototype expected by end of 2026 (⁴)

2025 · 5 events

2025-Q4 · Apr – Jun 2025

„Archer is not just designing chips; the team is building the technological backbone of tomorrow by eliminating key technical risks and solidifying the company's patent portfolio.“ – Greg English, Executive Chair ¹

Net income turned negative ◦ 2025-08-28
Net loss after income tax widened to AUD 6.97 million from AUD 4.80 million in prior year; share-based payments rose to AUD 1.89 million from AUD 0.60 million ¹

New market 2025-08-28
Launched TMR sensor program targeting AI, automotive, and IoT markets with prototypes built and early market feedback confirming commercial potential ¹

Strategic pivot 2025-08-28
Achieved strong coupling between spin states of proprietary carbon-based spin material and superconducting resonator through new resonator circuit design, a key qubit control milestone ¹

2025-Q3 · Jan – Mar 2025

Strategic pivot 2025-08-28
Dr Simon Ruffell appointed Chief Executive Officer on 27 March 2025, transitioning from Chief Technology Officer role ¹

2025-Q2 · Oct – Dec 2024

Strategic pivot 2025-08-28
Dr Mohammad Choucair departed as Chief Executive Officer effective 14 October 2024 ¹

Key Figures (A$m)#

The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). Each row is one period, most recent first. Values with a dotted underline are clickable and show the raw value, the exact source location, the scale evidence and the source; derived values additionally show their formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.

All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.

Basis Metric

Net income (A$m) · quarterly basis, as reported

EPS (A$) · quarterly basis, as reported

Operating cash flow (A$m) · quarterly basis, as reported

Cash (A$m) · annual basis, as reported

Cash (A$m) · quarterly basis, as reported

Fiscal years

Amounts in A$m · EPS in A$ per share · as reported

Period	Calendar quarter	Published	Net income	EPS (A$)	FCF	Cash	Source
FY2026*	Q3/2025–Q2/2026	2026-06-30	-6.4	-2.50	-5.1	1.8	⁵
FY2025	Q3/2024–Q2/2025	2025-12-31	-7	-2.74	–	2.7	¹⁰¹
FY2024	Q3/2023–Q2/2024	2025-12-31	-4.8	-1.88	–	2.8	¹⁰¹
FY2023	Q3/2022–Q2/2023	2025-12-31	–	–	–	0.8	¹⁰¹

* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.

Publication date of individual rows is a publisher placeholder (not the actual publication date).

Columns not reported in this reporting cadence are hidden: Revenue, Op. income, Op. income (adj.), EBITDA (adj.), EPS adj., Net Debt, Net Debt/EBITDA (not reported in any source for these periods).

Balance Sheet & Cash Flow (A$m)#

Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. Balance sheet values are as of the period end, flow items cover the period. Derived values are marked and are calculated, for example, as: net debt = financial debt − cash; free cash flow = operating cash flow − capex; the click popover shows formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.

Fiscal years

Amounts in A$m · as reported

Period	Calendar quarter	Published	Cash	OCF	Capex	FCF	Source
FY2026	Q3/2025–Q2/2026	2026-06-30	1.8	-5.1	0	-5.1	⁵
FY2025	Q3/2024–Q2/2025	2025-12-31	2.7	-4.2	–	–	¹⁰¹
FY2024	Q3/2023–Q2/2024	2025-12-31	2.8	-4.8	–	–	¹⁰¹
FY2023	Q3/2022–Q2/2023	2025-12-31	0.8	–	–	–	¹⁰¹

Quarters

Amounts in A$m · as reported

Period	Calendar quarter	Published	Cash	Source
2025-Q4	Q2/2025	2025-12-31	2.7	¹⁰⁶
2024-Q4	Q2/2024	2025-12-31	2.8	¹⁰⁶
2023-Q4	Q2/2023	2025-12-31	0.8	¹⁰¹

Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.

Publication date of individual rows is a publisher placeholder (not the actual publication date).

Products & M&A (15/15 active+recent)#

Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. “Active/current” means: still mentioned in the most recent reports; what the company no longer mentions moves to the expandable part but is never deleted. Rows in grey are discontinued products.

Product/Line	Since	Status	Source
Share Purchase Plan for eligible shareholders in Australia and New Zealand	2026-12	Launched	⁵
Biochip beta prototype external laboratory evaluation and pre-clinical studies	2026-12	Launched	⁵
12CQ quantum chip foundry-ready demonstration	2026-12	Launched	⁵
$7 million share placement	2026-12	Launched	⁵
Qubit demonstration	2026-06	Launched	¹
Biochip integrated alpha prototype completion	2026-06	Launched	⁶
Quantum qubit demonstrator device	2026	Launched	⁴
IMEC collaboration expansion to silicon-based sensors	2026	Launched	⁶
Full Quantum Machine Learning prototype for fraud detection	2026	Launched	⁴
Biochip clinical trials prototype (2x)	2026	Launched	¹
Biochip beta prototype development commencement	2026	Launched	⁶
Beta-prototype of blood potassium Biochip	2026	Launched	⁴
Blood potassium sensing lab demonstration	2025-12	Launched	¹
CSIRO joint project for quantum machine-learning software	2025-11	Launched	⁶
TMR sensor commercialisation pathway establishment	2025	Launched	¹

M&A (3)#

All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Purchase prices appear only where the company itself has disclosed them. Rows in grey are cancelled transactions; the cancellation date is shown in the row.

Acquisitions · 2Divestitures/exits · 1

Acquisitions

Transaction / stake	Date	Type	Source
IonQ Quantum Compute Agreement (2x)	2026-07	Announced	⁵
ChemX Materials Limited appointment of voluntary administrators	2025-01	Completed	¹

Divestitures / exits

Transaction / stake	Date	Type	Source
ChemX Materials Limited ASX suspension	2024-12	Divested	¹

Reported KPIs (as disclosed) (30)#

Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. These “story KPIs” usually slip through standard databases; here they are collected as reported, with no calculation of our own. Important: the definition comes from the company itself and can differ from firm to firm; period and source are stated next to every value.

Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.

Date	Period	KPI	Value / change	Source
2026-08-26	FY2026	Unlisted options on issue	17,250,000	⁶
2026-08-26	FY2026	Shares on issue	254,847,013	⁶
2026-08-26	FY2026	Performance rights on issue	2,114,960	⁶
2026-08-26	FY2026	Net tangible assets per share	3.96 cents	⁶
2026-08-26	FY2026	Interest income	479,104	⁶
–	2026-Q4	Estimated quarters of funding available	4.51 (AUD thousands)	⁵
–	2026-Q4	Call deposits	6,560 (AUD $A'000)	⁵
–	2026-Q4	Bank balances	1,846	⁵
–	2026-Q3	Staff costs YTD	(2,654)	⁴
–	2026-Q3	Staff costs	(852)	⁴
–	2026-Q3	Research and development payments YTD	(2,080)	⁴
–	2026-Q3	Research and development payments	(680)	⁴
–	2026-Q3	Interest received YTD	596	⁴
–	2026-Q3	Interest received	39	⁴
–	2026-Q3	Government grants and tax incentives YTD	2,102	⁴
–	2026-Q3	Government grants and tax incentives	2,102	⁴
–	2026-Q3	Cash position	$10.3 million	⁴
–	2026-Q3	Administration and corporate costs YTD	(1,212)	⁴
–	2026-Q3	Administration and corporate costs	(473)	⁴
2025-08-28	FY2025	Term deposits short term	11,082,750	¹
2025-08-28	FY2025	Loss after income tax	(6,972,006)	¹
2025-08-28	FY2025	Listed investment in Volatus Capital Corp shares	73,100	¹
2025-08-28	FY2025	Interest income	743,288	¹
2025-08-28	FY2025	Unlisted share options	17,250,000	¹
2025-08-28	FY2025	Total comprehensive loss for the year	(6,972,006)	¹
2025-08-28	FY2025	Share-based payments expense	1,889,842	¹
2025-08-28	FY2025	Quantum and biochip technology research expenditure	4,791,577	¹
2025-08-28	FY2025	Ordinary shares on issue	254,847,013	¹
2025-08-28	FY2025	Fair value loss on financial assets	455,227	¹
2025-08-28	FY2025	Depreciation expense	133,445	¹

▸ Earlier KPIs (+15)

Development#

A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Most recent period first, grouped by year; each text is written from the original report of that period, superscript numbers lead to the source.

FY2026

Archer Materials Limited reported a net loss of A$6.4 million and diluted EPS of -2.5 cents for FY2026, with cash and cash equivalents of A$1.8 million at 30 June 2026, reflecting its status as a pre-revenue technology company (⁶). The net loss narrowed by approximately 8.8% compared to FY2025, attributable to a reduction in non-cash share-based payments expense rather than a change in underlying research activity (⁶). The company advanced its 12CQ carbon-based quantum chip program, synthesising qubit material on a one-inch silicon wafer and demonstrating electron spin lifetimes exceeding 0.4 microseconds at room temperature, and completed an integrated Biochip alpha prototype while commencing beta prototype development (⁶). A quantum machine-learning collaboration with CSIRO for financial fraud detection commenced in November 2025, and a three-year Quantum Compute Agreement with IonQ was signed on 1 July 2026 providing access to commercial quantum hardware and specialist engineering support (⁶). Subsequent to year end, the company raised approximately A$7.8 million before costs through a share placement and Share Purchase Plan to fund ongoing program execution (⁶).

FY2025

Archer Materials Limited recorded a net loss after income tax of AUD 6.97 million for FY2025, compared to AUD 4.80 million in the prior year, with the increase driven in part by higher share-based payments of AUD 1.89 million versus AUD 0.60 million in FY2024 ¹. Net cash decreased by approximately AUD 4.47 million to AUD 13.74 million over the year, partially offset by a research and development tax incentive receivable of AUD 2.06 million recognised for the period ¹. Leadership transitioned during the year, with Dr Mohammad Choucair departing as Chief Executive Officer in October 2024 and Dr Simon Ruffell, previously Chief Technology Officer, appointed to the role in March 2025 ¹. The company advanced multiple milestones across its qubit processor, Biochip biosensor, and TMR magnetic sensor programs, including achieving strong coupling between spin states of proprietary carbon-based spin material and a superconducting resonator, a 97% reduction in gFET chip size enabling up to 1,375 chips per four-inch wafer, and the launch of a new TMR sensor program targeting AI, automotive, and IoT markets ¹. The investment in ChemX Materials Limited was written down to zero following ChemX's ASX suspension in December 2024 and appointment of voluntary administrators in January 2025 ¹.

Sources: official investor relations documents#

All original documents used, with type (e.g. quarterly, half-year, annual report), publication date and a direct link to the filing (EDINET/SEC/IR). Every superscript number in the report points to an entry in this list; so every figure can be traced back to its place in the original.

6 documents · 2026 – 2026 · IR

#	Document type	Published	Link
#1 / #101	IR-Annual	–	Open
#4	IR-Quarter	–	Open
#5	IR-Quarter	–	Open
#2	IR-Quarter	2026-05-04	Open
#3	IR-Report	2026-06-04	Open
#6 / #106	IR-Annual	2026-08-26	Open

FAQ#

Where can I find the official investor relations documents of Archer Materials Limited?

The sources chapter links all 8 original filings used (IR documents) with type, publication date and a direct link; every figure in the report carries a source number.